NDSAC - Nomination sought for Committee membership
The National Drug Scheduling Advisory Committee (NDSAC) is soliciting nominations to fill a membership vacancy
Pharmacy Technician Bridging Education Program-Course and PLAR exam schedules
Please note, this section will be updated periodically as the information becomes available.
Reminder: Courses and PLAR exams available in both English and French
NOTE: Selkirk College registration deadline for all English and French courses beginning in September 2016 is August 25, 2016
Rappel : Les cours et les examens ERA sont offerts en français et en anglais
REMARQUE : La date limite pour l’inscription aux cours (anglais et français) débutant en septembre 2016 au collège Selkirk est le 25 août 2016
Registration deadlines for all institutions are available on the Course and PLAR Schedules page.
Registration for all courses is conducted directly with the educational institution offering the program.
NDSAC Meeting of September 12-13, 2016
The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for September 12-13, 2016 is cancelled.
The next meeting of the Committee is scheduled for December 5-6, 2016. The deadline to receive submissions for a drug scheduling application for this meeting is by end of day Thursday, October 6, 2016.
Health Product Risk Communication
BLINCYTO (blinatumomab) and Pancreatitis - Amgen Canada Inc.
There have been reported cases of life-threatening, sometimes fatal pancreatitis associated with the use BLINCYTO (blinatumomab). The Canadian Product Monograph has been updated to reflect this new safety information.
Health Canada Health Product Risk Communication
National Drug Schedules: Final Recommendation on naloxone hydrochloride
The Interim Recommendation made by the National Drug Scheduling Advisory Committee (NDSAC) on June 13, 2016, subsequent to their meeting of June 6, 2016, was finalized effective June 24, 2016. The final recommendation is as follows:
• Naloxone hydrochloride injection, when indicated for emergency use for opioid overdose outside hospital settings – be granted Schedule II status
Alere Inc. initiating voluntary withdrawal of Alere INRatio® and INRatio® 2 PT/INR Monitoring System that may pose serious health risks
Alere Inc. is withdrawing the Alere INRatio® and INRatio®2 Prothrombin Time Monitoring Systems (professional and self-test) devices from the Canadian market. These devices measure blood clotting time in patients requiring warfarin and other oral blood-thinning medicines. There is a risk that the Alere devices provide an inaccurate low reading.
Health Canada Advisory